RAS/RAF
Oncology
DiscoveryActive
Key Facts
About Qubit Pharmaceuticals
Qubit Pharmaceuticals is a Paris-based, private biotech firm pioneering a quantum-aided drug discovery platform. The company integrates decades of computational chemistry research into its ATLAS platform, which uses quantum mechanics, AI, and hybrid HPC/quantum computing to generate and simulate novel drug candidates with high precision. With a team of over 60 experts and a pipeline of over 20 programs, Qubit is targeting historically undruggable targets in oncology and inflammation while actively seeking partnerships to expand its impact.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| Bi-XDC with PROTACs | Coherent Biopharma | IND-enabling |
| Bi-XDC with RPT | Coherent Biopharma | Early-stage |
| mRNA Anticancer Vaccine | Sunshine Biopharma | Preclinical Research |
| Biosimilar Bevacizumab | Organon (2) | Phase 3 |
| Biosimilar Pembrolizumab | Organon (2) | Phase 3 |
| BCL-2 Inhibitor Program | Vincerx Pharma | Preclinical |
| Not specified in provided content | 3Sbio | Various |
| Preclinical Projects | Zion Pharma | Preclinical |
| Attenukine Oncology Candidate | Teva | Phase 1 |
| XEMA Tumor Marker ELISA Kit | XEMA Group | Commercial |
| KRAS inhibitor | Risen Pharma Tech | Preclinical/Phase 1 |
| KEAP1 Activator Program | Vividion Therapeutics | Phase 1 |